Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 330Terminated 68Unknown 20Withdrawn 19Active not recruiting 16Recruiting 14Suspended 2Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 430Neoplasms 284Carcinoma, Non-Small-Cell Lung 266Colorectal Neoplasms 228Lung Neoplasms 173Prostatic Neoplasms 171Carcinoma, Hepatocellular 156Stomach Neoplasms 129Leukemia, Myeloid, Acute 118Pancreatic Neoplasms 115Multiple Myeloma 105Recurrence 96Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 88Neoplasm Metastasis 87Rectal Neoplasms 85Ovarian Neoplasms 77Triple Negative Breast Neoplasms 75Small Cell Lung Carcinoma 72Head and Neck Neoplasms 68Brain Neoplasms 68Esophageal Neoplasms 64Glioblastoma 63Colonic Neoplasms 60Endometrial Neoplasms 58Melanoma 54Hematologic Neoplasms 53Motor Activity 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Nasopharyngeal Carcinoma 46

Interventions

cemiplimab 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Gliosarcoma × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡